A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
Public ClinicalTrials.gov record NCT05958407. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Interventional, Adaptive, Clinical Trial to Evaluate the Efficacy and Safety of Tralokinumab 300 mg Every Second Week Monotherapy Compared With Placebo in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
Study identification
- NCT ID
- NCT05958407
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- LEO Pharma
- Industry
- Enrollment
- 235 participants
Conditions and interventions
Conditions
Interventions
- Tralokinumab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 27, 2023
- Primary completion
- May 4, 2025
- Completion
- Sep 21, 2025
- Last update posted
- Jan 5, 2026
2023 – 2025
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| LEO Pharma Investigational Site | Birmingham | Alabama | 35209 | — |
| LEO Pharma Investigational Site | Fort Smith | Arkansas | 72916 | — |
| LEO Pharma Investigational Site | Fountain Valley | California | 92708 | — |
| LEO Pharma Investigational Site | Los Angeles | California | 90025 | — |
| LEO Pharma Investigational Site | Sacramento | California | 95816 | — |
| LEO Pharma Investigational Site | Farmington | Connecticut | 06032 | — |
| LEO Pharma Investigational Site | Hialeah | Florida | 33012 | — |
| LEO Pharma Investigational Site | Plainfield | Indiana | 46168 | — |
| LEO Pharma Investigational Site | Louisville | Kentucky | 40217 | — |
| LEO Pharma Investigational Site | New Orleans | Louisiana | 70115 | — |
| LEO Pharma Investigational Site | Bangor | Maine | 04401 | — |
| LEO Pharma Investigational Site | Caledonia | Michigan | 49316 | — |
| LEO Pharma Investigational Site | Detroit | Michigan | 48202 | — |
| LEO Pharma Investigational Site | Portsmouth | New Hampshire | 03801 | — |
| LEO Pharma Investigational Site | Cortland | New York | 13045 | — |
| LEO Pharma Investigational Site | New York | New York | 10075 | — |
| LEO Pharma Investigational Site | Portland | Oregon | 97201 | — |
| LEO Pharma Investigational Site | Portland | Oregon | 97210 | — |
| LEO Pharma Investigational Site | Nashville | Tennessee | 37211 | — |
| LEO Pharma Investigational Site | Dallas | Texas | 75225 | — |
| LEO Pharma Investigational Site | Frisco | Texas | 75034 | — |
| LEO Pharma Investigational Site | San Antonio | Texas | 78213 | — |
| LEO Pharma Investigational Site | Webster | Texas | 77598 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05958407, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05958407 live on ClinicalTrials.gov.